Who has been buying Oreum Therapeutic stock?

2 distinct insiders have filed 0 disclosed insider purchases in Oreum Therapeutic (475830), most recently on 2026-06-01. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Oreum Therapeutic have?

Oreum Therapeutic has 0 buy-side and 5 sell-side disclosures on record, covering ₩23.0B ($16.0M) in total reported value, spanning 2025-02-14 to 2026-06-01.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Oreum Therapeutic 475830

Company

오름테라퓨틱Oreum Therapeutic

Insiders

Buys

Total Value

₩23.0B ($16.0M)

Avg Return

-75.51%

Last Filing

2026-06-01

Oreum Therapeutic (475830) has 0 disclosed insider purchases and 5 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩23.0B ($16.0M) in reported transaction value. The earliest filing StockDrifts holds for Oreum Therapeutic is dated 2025-02-14; the most recent is 2026-06-01. Across these filings the average return since disclosure is -75.51%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-01	BUY	주식매수선택권	김병우 Kim Byeong-woo	thanks	3.3K	₩63,700	-0.8%	₩210M ($146K)
2026-06-01	BUY	주식매수선택권	PETER UNNAM PARK	Other non-executive directors	100.0K	₩63,700	-0.8%	₩6.4B ($4.4M)
2026-03-25	SELL	Market Sell	PETER UNNAM PARK	Other non-executive directors	-9.0K	₩112,100	-0.3%	₩1.0B ($701K)
2026-03-24	SELL	Market Sell	PETER UNNAM PARK	Other non-executive directors	-30.0K	₩110,600	-1.6%	₩3.3B ($2.3M)
2025-12-01	SELL	Market Sell	인터베스트 Intervest	-	-85.0K	₩62,500	-109.1%	₩5.3B ($3.7M)
2025-11-28	SELL	Market Sell	인터베스트 Intervest	-	-150.0K	₩57,000	-129.3%	₩8.6B ($5.9M)
2025-11-27	SELL	Market Sell	인터베스트 Intervest	-	-87.7K	₩55,100	-137.2%	₩4.8B ($3.4M)
2025-02-14	BUY	신규상장	이승주 Seungju Lee	CEO	3.4M	₩21,800	+499.5%	₩73.9B ($51.3M)
2025-02-14	BUY	신규상장	PETER UNNAM PARK	Other non-executive directors	60.0K	₩21,800	+499.5%	₩1.3B ($908K)
2025-02-14	BUY	신규상장	정인태 Jeong In-tae	moving	10.0K	₩21,800	+499.5%	₩218M ($151K)
2025-02-14	BUY	신규상장	인터베스트 Intervest	-	2.3M	₩21,800	+499.5%	₩49.3B ($34.3M)

Frequently asked questions

Who has been buying Oreum Therapeutic stock?: 2 distinct insiders have filed 0 disclosed insider purchases in Oreum Therapeutic (475830), most recently on 2026-06-01. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Oreum Therapeutic have?: Oreum Therapeutic has 0 buy-side and 5 sell-side disclosures on record, covering ₩23.0B ($16.0M) in total reported value, spanning 2025-02-14 to 2026-06-01.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.